Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Neuroscience, School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Neuroscience, School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
World Neurosurg. 2021 Dec;156:125-132. doi: 10.1016/j.wneu.2021.09.027. Epub 2021 Sep 13.
A chordoma is a slow-growing, invasive neoplasm in the neuraxis that is thought to arise from notochordal cells. At 10-year follow-up, the average survival rate is 50%, though individual prognosis varies substantially. We aimed to provide a comprehensive overview of the genes and proteins expressed in these tumors and their prognostic value to facilitate prognostication for patients with chordoma.
A systematic search of clinical studies that investigated expressed factors related to chordoma survival was performed in PubMed. Data extracted included RNA and protein expression data and prognostic value (in terms of overall survival, progression-free survival, disease-free survival, and recurrence-free survival) from univariate and multivariate analyses.
This review included 78 original studies that collectively evaluated 134 expressed factors. Of these molecular factors, 96 by univariate analysis and 32 by multivariate analysis had a predictive value for patient survival. Of the molecular factors studied in multivariate analyses, 26 factors had a negative effect while 6 had a positive effect on patient survival.
Identification of molecular factors that are associated with survival contributes to better prognostication of patients with chordoma. Given the rarity of chordoma, often only univariate analyses can be performed. Robust multivariate analyses are scarcer but provide independently significant prognostic factors. The data presented in this review can aid in prognostication for the individual patient and facilitate the development of targeted therapies.
脊索瘤是一种生长缓慢、侵袭性的神经轴内肿瘤，被认为起源于脊索细胞。10 年随访时，平均生存率为 50%，但个体预后差异很大。我们旨在全面概述这些肿瘤中表达的基因和蛋白质及其预后价值，以帮助预测脊索瘤患者的预后。
在 PubMed 中对探讨与脊索瘤生存相关的表达因子的临床研究进行了系统检索。提取的数据包括来自单变量和多变量分析的 RNA 和蛋白质表达数据以及预后价值（总生存、无进展生存、无病生存和无复发生存）。
本综述共纳入 78 项原始研究，共评估了 134 个表达因子。在这些分子因子中，96 个通过单变量分析，32 个通过多变量分析具有预测患者生存的价值。在多变量分析中研究的分子因子中，26 个具有负效应，6 个具有正效应。
鉴定与生存相关的分子因子有助于更好地预测脊索瘤患者的预后。鉴于脊索瘤的罕见性，通常只能进行单变量分析。稳健的多变量分析更为罕见，但提供了独立的显著预后因素。本综述中提供的数据可以帮助预测个体患者的预后，并促进靶向治疗的发展。
